Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30854556 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL29401188 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL29401751 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL2307942 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL800091 | 1.00 | MDM4 (0.57) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL29516375 | 0.93 | MDM4 (0.53) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL430008 | 0.93 | MDM2 (0.56) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL30861860 | 0.93 | MDM2 (0.56) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL3732565 | 0.93 | MDM2 (0.56) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL3733904 | 0.93 | MDM2 (0.56) | MDM4TP53MDM2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| EP-4732286-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | Board of Regents, The University of Texas System (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| US-20250298027-A1 | METHOD OF EVALUATING SMALL MOLECULE DISTRIBUTION USING TELLUROPHENE ANALOGUES | UNIVERSITY HEALTH NETWORK (CA) | 2025-09-25 | — | — | US | disclosed |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | ARIAD PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030087832-A1 | Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity | AVENTIS PHARMACEUTICALS INC. | 2003-05-08 | — | — | US | disclosed |
| US-6548637-B1 | Endomorphine analog analgesics | SEPRACOR, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20030045480-A1 | Method of treating hyperresorptive bone disorders | ARIAD PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1140984-B1 | SELECTIVE INHIBITORS OF MMP-12 | AVENTIS PHARMA INC (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6352976-B1 | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASE FOR EMPHYSEMA | AVENTIS PHARMACEUTICALS INC. | 2002-03-05 | — | — | US | disclosed |
| EP-1140984-A1 | SELECTIVE INHIBITORS OF MMP-12 | Aventis Pharmaceuticals Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001070684-A2 | PEPTIDOMIMETIC LIGANDS FOR CELLULAR RECEPTORS AND ION CHANNELS | SEPRACOR, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2000040600-A1 | SELECTIVE INHIBITORS OF MMP-12 | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999065932-A1 | TETRAPEPTIDES, ANALOGS AND PEPTIDOMIMETICS WHICH BIND SELECTIVELY MAMMALIAN OPIOID RECEPTORS | SEPRACOR, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045480-A1 | Method of treating hyperresorptive bone disorders | SRC, GRB2, ACP1 | MDM4 2636/4885TP53 3481/4885MDM2 2492/4885 |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | MDM4 3415/4885TP53 3318/4885MDM2 2867/4885 |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | MDM4 2089/4885TP53 826/4885MDM2 1933/4885 |
| US-20250298027-A1 | METHOD OF EVALUATING SMALL MOLECULE DISTRIBUTION USING TELLUROPHENE ANALOGUES | SNRPE, SNRPA, SLC5A7 | MDM4 1320/4885TP53 328/4885MDM2 578/4885 |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | SRC, CTTN, YES1 | MDM4 2715/4885TP53 1918/4885MDM2 1185/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MDM4 1648/4885TP53 614/4885MDM2 423/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM4 441/4885TP53 34/4885MDM2 164/4885 |
| US-20030087832-A1 | Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity | SRC, CHUK, DSTYK | MDM4 1949/4885TP53 1172/4885MDM2 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.